ad-214
mAbexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 19, 2020 (NCT04415671)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- C-X-C chemokine receptor type 4INHIBITOR
CXCR4 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314974 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05914909 | Phase 1 | Aug 31, 2023 | AdAlta Limited, CMAX Clinical Research |
| NCT05062876 | Phase 1 | Nov 3, 2021 | Addpharma Inc., Seoul National University |
| NCT04494243 | Phase 1 | Aug 28, 2020 | Addpharma Inc., Seoul National University |
| NCT04415671 | Phase 1 | Jul 19, 2020 | AdAlta Limited |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AdAlta Limited | For profit | 2 | 2 | 1 | 2020 |
| Addpharma Inc. | For profit | 2 | 2 | 1 | 2020 |
| Seoul National University | Academic/Hospital | 2 | 0 | 1 | 2020 |
| CMAX Clinical Research | For profit | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1